- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04527796
Influence of a Residential Rehabilitation Program on Body Composition in Patients With Cystic Fibrosis
Influence of a Residential Rehabilitation Program on Body Composition in Patients With Cystic Fibrosis (Children and Adults)
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
De Haan, Belgium, 8420
- Zeepreventorium de Haan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Cystic fibrosis
- stay at the rehabilitation center for at least 3 consecutive weeks
Exclusion Criteria:
- steroid use
- absence from the program for more than 2 consecutive days
Study Plan
How is the study designed?
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
rehabilitation
All included patients get an pre-intervention and a post intervention analysis
|
During the rehabilitation program a multidisciplinary team, consisting of a pneumologist, dietician, psychologist, social worker and several physiotherapists, coach the cystic fibrosis patients. The physiotherapists help with autogenic drainage and aerosol therapy (2-3 times/day) and supervise physical activity (5, 1-hour lasting, training sessions/week: swimming 2, Fitness training 2, 1 session of choice). The dietician calculates basal and theoretical energy needs . A carbohydrate-rich snack before exercise, to improve exercise tolerance and a carbohydrate-protein-rich snack afterwards to improve recuperation is provided. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
body composition change
Time Frame: day 0 and day 21 (start and end of the rehabilitation program)
|
Dual energy X-ray absorptiometry measured Fat mass index (kg/m*2)
|
day 0 and day 21 (start and end of the rehabilitation program)
|
body composition change
Time Frame: day 0 and day 21 (start and end of the rehabilitation program)
|
Dual energy X-ray absorptiometry measured fat free mass (kg/m*2)
|
day 0 and day 21 (start and end of the rehabilitation program)
|
Body mass index change
Time Frame: day 0 and day 21 (start and end of the rehabilitation program)
|
calculated based on weight and height (kg/m*2) converted in standard deviations
|
day 0 and day 21 (start and end of the rehabilitation program)
|
Weight change
Time Frame: day 0 and day 21 (start and end of the rehabilitation program)
|
Scale weighed weight (kg) converted in standard deviations of normal population of normal populations
|
day 0 and day 21 (start and end of the rehabilitation program)
|
pulmonary function change
Time Frame: day 0 and day 21 (start and end of the rehabilitation program)
|
forced expiratory volume in 1 second (% of normal)
|
day 0 and day 21 (start and end of the rehabilitation program)
|
pulmonary function change
Time Frame: day 0 and day 21 (start and end of the rehabilitation program)
|
Forced Vital capacity (% of normal)
|
day 0 and day 21 (start and end of the rehabilitation program)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Physical activity
Time Frame: Week 1
|
"SenseWear pro 3" armband measured physical activity
|
Week 1
|
dietary intake
Time Frame: 2 days/week for 3 consecutive weeks
|
macronutrient intake measured based on 2 days/week weighed nutritional intake
|
2 days/week for 3 consecutive weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Stephanie Van Biervliet, MD, PhD, Gent University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- B670201939582
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystic Fibrosis
-
Hospital de Clinicas de Porto AlegreUnknownCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children | Cystic Fibrosis With ExacerbationBrazil
-
University of Colorado, DenverCystic Fibrosis FoundationTerminatedCystic Fibrosis-related Diabetes | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in ChildrenUnited States
-
Royal College of Surgeons, IrelandThe Hospital for Sick Children; Imperial College London; Erasmus Medical Center; University College Dublin and other collaboratorsActive, not recruitingCystic Fibrosis | Adherence, Medication | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in Children | Cystic Fibrosis Liver DiseaseUnited Kingdom, Ireland
-
Herlev and Gentofte HospitalCopenhagen University Hospital, DenmarkActive, not recruitingMyocardial Infarction | Heart Diseases | Heart Failure | Stroke | Cystic Fibrosis | Heart Failure, Diastolic | Heart Failure, Systolic | Left Ventricular Dysfunction | Cystic Fibrosis-related Diabetes | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of Pancreas | Cystic Fibrosis, Pulmonary | Cystic...Denmark
-
The Hospital for Sick ChildrenCanadian Cystic Fibrosis FoundationActive, not recruitingCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in ChildrenCanada
-
Arrowhead PharmaceuticalsTerminatedCystic Fibrosis, PulmonaryAustralia, New Zealand
-
AzurRx SASCompletedCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of PancreasTurkey, Hungary
-
Dartmouth-Hitchcock Medical CenterTrustees of Dartmouth CollegeWithdrawnCystic Fibrosis-related Diabetes | Cystic Fibrosis Liver Disease | CF - Cystic FibrosisUnited States
-
University Hospital, BordeauxCompleted
-
University of PortsmouthUniversity Hospital Southampton NHS Foundation Trust; Loughborough University; Queen Alexandra HospitalTerminated
Clinical Trials on Rehabilitation
-
Tuba MadenCompletedMultiple Sclerosis | Postural Balance | Cervical Region Disorder Nos | Muscle Tonus | ProprioceptionTurkey
-
IRCCS San Camillo, Venezia, ItalyIRCCS San Raffaele; Istituto Universitario di Studi Superiori PaviaRecruitingStroke | Schizophrenia | Traumatic Brain InjuryItaly
-
I.R.C.C.S. Fondazione Santa LuciaCompleted
-
Hopital FochRecruitingSpinal Cord InjuriesFrance
-
Istituti Clinici Scientifici Maugeri SpANot yet recruitingCognitive Impairment | Dementia | Vascular Dementia | Dementia, Mixed | Comorbidities and Coexisting Conditions
-
Azienda Ospedaliera Città della Salute e della...CompletedAdolescent | Child | Hematopoietic Stem Cell TransplantationItaly
-
Centre Hospitalier Universitaire de Saint EtienneMinistry of Health, FranceRecruitingPulmonary Arterial HypertensionFrance
-
Campus Bio-Medico UniversityRecruitingLow Back Pain | Rehabilitation | Orthopedic Disorder | Physical Therapy | Core StrengtheningItaly
-
Centre Hospitalier Universitaire de Saint EtienneMinistry of Health, FranceRecruitingAnterior Cruciate Ligament Rupture | Ligament Knee InjuryFrance, Switzerland
-
Shanghai University of Traditional Chinese MedicineFudan UniversityRecruiting